11 November 2026
Oncology Clinical Trials in South Korea: ADC Landscape

Oncology Clinical Trials in South Korea: How In-Label IITs Speed Up ADC Evidence
South Korea’s antibody drug conjugate (ADC) market is still maturing, but its developers are attracting major global partners. In October 2025, AimedBio signed a license agreement worth up to $991 million with Boehringer Ingelheim for one of its ADCs. In October 2026, the first patient was dosed in a Phase I study of that ADC, now called BI 4060107. In December 2023, LigaChem Biosciences (formerly LegoChem Biosciences) signed a license agreement worth up to $1.7 billion with Janssen for a Trop2-directed ADC.
These deals point to where the opportunity lies: not simply in selling ADCs in Korea, but in developing them from Korea for the global market.
For oncology sponsors weighing clinical trials in South Korea, or deciding whom to partner with, the regulatory timing adds to the case. South Korea’s Ministry of Food and Drug Safety (MFDS) has set a 240-day target for the approval and review of eligible new drugs under its Medical Product Approval and Review Innovation Plan (announced in a May 28, 2026 press release), with guidelines in effect since June 1, 2026, and the full timeline applying to new applications as of October 1, 2026. Read on to understand how the ADC landscape is taking shape, what Korean clinicians want from ADC development, and where investigator-initiated trials (IITs) fit.












